Format

Send to

Choose Destination
Nutrients. 2017 Oct 14;9(10). pii: E1122. doi: 10.3390/nu9101122.

Resveratrol and Amyloid-Beta: Mechanistic Insights.

Author information

1
Department of Neuropharmacology, Research Institute of Medicine and Pharmacy, Qiqihar Medical University, Qiqihar 161006, China. yongmingjiahlj@126.com.
2
Department of Pathophysiology, Qiqihar Medical University, Qiqihar 161006, China. christina85721@163.com.
3
Department of Neuropharmacology, Research Institute of Medicine and Pharmacy, Qiqihar Medical University, Qiqihar 161006, China. lxw_qmu@126.com.

Abstract

The amyloid-beta (Aβ) hypothesis that dyshomeostasis between Aβ production and clearance is a very early, key molecular factor in the etiology of Alzheimer's disease (AD) has been proposed and examined in the AD research field. Scientists have focused on seeking natural products or drugs to influence the dynamic equilibrium of Aβ, targeting production and clearance of Aβ. There is emerging evidence that resveratrol (Res), a naturally occurring polyphenol mainly found in grapes and red wine, acts on AD in numerous in vivo and in vitro models. Res decreases the amyloidogenic cleavage of the amyloid precursor protein (APP), enhances clearance of amyloid beta-peptides, and reduces Aβ aggregation. Moreover, Res also protects neuronal functions through its antioxidant properties. This review discusses the action of Res on Aβ production, clearance and aggregation and multiple potential mechanisms, providing evidence of the useful of Res for AD treatment.

KEYWORDS:

alzheimer disease; amyloid-beta; blood-brain-barrier; resveratrol; transporter

PMID:
29036903
PMCID:
PMC5691738
DOI:
10.3390/nu9101122
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center